Company
Headquarters: Taipei, Taiwan
CEO: Dr. Michael N. Chang PH.D.
TW$13.39 Billion
TWD as of July 1, 2024
US$411.1 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
OBI Pharma, Inc., a bio-pharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immuno-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-898 SSEA4, a passive immunity monoclonal antibody; OBI-998 SSEA4, an antibody small molecule drug complex, which targets toxic drugs to malignant tumors; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a clostridium botulinum toxin. The company was founded in 2002 and is based in Taipei, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
OBI Pharma, Inc. has the following listings and related stock indices.
Stock: TWSE: 4174 wb_incandescent